Dr Reddy’s launches oral suspension drug in the US market

Drug major Dr Reddy’s Laboratories Thursday announced the launch of Sevelamer Carbonate for oral suspension, used for controlling serum phosphorus in patients with chronic kidney disease on dialysis, in the US market.

The newly launched product is in the strengths of 0.8 g and 2.4 g packets, and is a therapeutic equivalent generic version of Renvela (sevelamer carbonate) for oral suspension, approved by the US Food and Drug Administration (USFDA), Dr Reddy’s Laboratories said in a BSE filing.

Quoting IMS Health data, the company said the Renvela brand and generic had US sales of approximately USD 101 million for the most recent 12 months ending in October 2018.

Shares of Reddy’s Laboratories were trading 0.64 per cent lower at Rs 2,601.45 apiece on BSE.

  • Related Posts

    IndiaAI, ICMR sign MoU to advance AI in healthcare

    New Delhi- IndiaAI on Thursday signed a memorandum of understanding (MoU) with the Indian Council of Medical Research (ICMR) to advance healthcare outcomes through the responsible and scalable application of…

    Illegal drug manufacturing racket busted in Baddi area

    In a major crackdown on the illegal drug trade, the Drugs Control Administration (DCA), Himachal Pradesh, on Friday busted a racket involved in the illicit manufacturing and storage of narcotic…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    IndiaAI, ICMR sign MoU to advance AI in healthcare

    IndiaAI, ICMR sign MoU to advance AI in healthcare

    Illegal drug manufacturing racket busted in Baddi area

    Illegal drug manufacturing racket busted in Baddi area

    US FDA and Telangana DCA bolster global pharma safety at second regulatory forum

    US FDA and Telangana DCA bolster global pharma safety at second regulatory forum

    Nishant as Health Minister, Bihar is all set to witness a New Dawn of Healthcare

    Nishant as Health Minister, Bihar is all set to witness a New Dawn of Healthcare

    Six Women Develop Serious Complications After C-Section

    Six Women Develop Serious Complications After C-Section

    Cracks Down on Pharma Biological Firm in Bagru; Labeling Violations, Unapproved Claims and Quality Lapses Detected

    Cracks Down on Pharma Biological Firm in Bagru; Labeling Violations, Unapproved Claims and Quality Lapses Detected